Ropes & Gray Represents China Biotech LianBio in Pfizer Strategic Collaboration
Ropes & Gray represented Shanghai-based biotechnology LianBio in a strategic collaboration with Pfizer to develop and commercialize therapeutic products in Greater China. The transaction was announced on November 19.
In addition to Pfizer’s participation in LianBio’s recent crossover financing, under the terms of the collaboration, Pfizer will contribute up to $70 million of non-dilutive capital toward in-licensing and co-development.
At LianBio’s discretion, products will be presented to Pfizer for joint development. Pfizer will have a right of first negotiation to obtain commercial rights to jointly developed therapies and each will carry separate financial considerations. During the collaboration, Pfizer may provide in-kind support for marketing, development and regulatory activities.
The Ropes & Gray team was led by life sciences partner Eric Wu (Shanghai).